Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 22.1% in February

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 344,000 shares, an increase of 22.1% from the February 13th total of 281,700 shares. Based on an average daily volume of 236,200 shares, the short-interest ratio is presently 1.5 days. Currently, 7.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Alliance Global Partners decreased their price target on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 19th. Ascendiant Capital Markets reiterated a “buy” rating and set a $6.60 price objective on shares of Vivos Therapeutics in a research report on Wednesday, November 20th.

Institutional Trading of Vivos Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC increased its holdings in Vivos Therapeutics by 23.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock worth $112,000 after buying an additional 5,000 shares during the last quarter. Cutter & CO Brokerage Inc. purchased a new position in Vivos Therapeutics during the fourth quarter valued at approximately $163,000. Geode Capital Management LLC grew its stake in Vivos Therapeutics by 55.6% during the fourth quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after acquiring an additional 16,025 shares in the last quarter. Finally, Anson Funds Management LP purchased a new position in Vivos Therapeutics during the fourth quarter valued at approximately $1,041,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $3.58 on Tuesday. Vivos Therapeutics has a 52-week low of $1.91 and a 52-week high of $6.28. The company has a 50-day simple moving average of $4.06 and a 200 day simple moving average of $3.57. The company has a market capitalization of $21.09 million, a PE ratio of -0.63 and a beta of 7.47.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.